Trial Data, Recommendation, Manufacturing & Distribution Approval, and Recruitment Support Breakthrough Treatments - Research Report on Novo Nordisk, Novartis, GSK, Sanofi, and Neurocrine Biosciences

NEW YORK, July 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Novo Nordisk A/S (NYSE: NVO), Novartis AG (NYSE: NVS), GlaxoSmithKline plc (NYSE: GSK), Sanofi (NYSE: SNY), and Neurocrine Biosciences Inc. (NASDAQ: NBIX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Novo Nordisk A/S Research Report

On June 22, 2013, Novo Nordisk A/S (Novo Nordisk) released new data from its one-year extension study of Tresiba (insulin degludec) that showed patients with Type 2 diabetes, who were treated with Tresiba, have a statistically improved quality of life in terms of overall physical health, as compared to patients who were treated with insulin glargine. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk said, "The data presented show that Tresiba is able to effectively maintain glycaemic control whilst demonstrating significant physical health benefits." The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/f4ec_NVO ]

Novartis AG Research Report

On June 26, 2013, Novartis AG (Novartis) announced results of its GLACIAL, the second of three pivotal Phase III studies to investigate the efficacy and safety of omalizumab compared to placebo in the treatment of chronic spontaneous urticaria (CSU), a chronic and debilitating skin disease with intractable itch and hives. The results of the study supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU and showed that more than one third of omalizumab-treated patients in the study were completely itch- and hive-free by Week 12, compared to 5% of placebo-treated patients.  Tim Wright, Global Head of Development at Novartis Pharmaceuticals, commented, "This is encouraging news for people living with CSU, whose quality of life is greatly impacted by this serious disease and who currently have few treatment options." Wright continued, "Novartis is committed to doing all we can for these patients by working to develop an important advance in CSU treatment, where unmet medical need remains high." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/956c_NVS ]

GlaxoSmithKline plc Research Report

On June 28, 2013, GlaxoSmithKline plc (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for the Company's two cancer drugs. The Company also expects CHMP to recommend marketing authorizations for Tafinlar (dabrafenib) and Tyverb (lapatinib), as a positive opinion from CHMP is one of the final steps of receiving marketing authorization. Dr. Rafael Amado, Head of Oncology R&D, GlaxoSmithKline, stated, "We are delighted by the positive opinions issued by CHMP on lapatinib and dabrafenib. They represent evidence of our commitment to patients living with cancer and they could bring new treatment options for European patients living with specific types of advanced breast cancer and melanoma." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/2737_GSK ]

Sanofi Research Report

On June 28, 2013, Sanofi announced that Japan's Ministry of Health, Labour, and Welfare has approved the manufacturing and distribution of Lyxumia (lixisenatide) for the treatment of type 2 diabetes. Lyxumia, the first once-daily prandial GLP-1 receptor agonist (RA) and the first GLP-1 RA approved in Japan for use in combination with basal insulin. Pierre Chancel, Senior Vice-President, Global Diabetes at Sanofi, commented, "Lyxumia, as the first GLP-1 receptor agonist approved in Japan for use in combination with basal insulin, will be a valuable new treatment option for many of the country's 6 million plus people living with type 2 diabetes." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/26eb_SNY ]

Neurocrine Biosciences Inc. Research Report

On July 1, 2013, Neurocrine Biosciences Inc. (Neurocrine Biosciences) announced that it has successfully completed the recruitment for the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. Neurocrine Biosciences reported that the design of the 12-week study is a randomized, parallel, double-blind, placebo-controlled trial of 120 subjects with moderate to severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. The Company also reported that topline data from the placebo-controlled portion of the trial is expected in approximately 10 weeks. Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences, said, "We are pleased with the baseline characteristics of subjects who have been randomized into this study and the conduct thus far of this clinical trial has been outstanding." O'Brien continued, "Completing enrollment of this Phase IIb study is another milestone in the development of NBI-98854 and we look forward to sharing the top-line results shortly." The Full Research Report on Neurocrine Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/8125_NBIX ]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED